These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 16610400)
1. Do thiazolidinediones cause heart failure? A critical review. Tang WH Cleve Clin J Med; 2006 Apr; 73(4):390-7. PubMed ID: 16610400 [TBL] [Abstract][Full Text] [Related]
2. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lago RM; Singh PP; Nesto RW Lancet; 2007 Sep; 370(9593):1129-36. PubMed ID: 17905165 [TBL] [Abstract][Full Text] [Related]
3. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials]. De Flines J; Scheen AJ Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661 [TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Patel C; Wyne KL; McGuire DK Diab Vasc Dis Res; 2005 May; 2(2):61-6. PubMed ID: 16305060 [TBL] [Abstract][Full Text] [Related]
5. Research profile. Is there a link? TZDs and congestive heart failure. Andrew Karter, PhD. Kordella T Diabetes Forecast; 2004 Jun; 57(6):98-100. PubMed ID: 15195634 [No Abstract] [Full Text] [Related]
6. Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure. Granberry MC; Hawkins JB; Franks AM Am J Health Syst Pharm; 2007 May; 64(9):931-6. PubMed ID: 17468147 [TBL] [Abstract][Full Text] [Related]
7. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits. Patel RR Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087 [TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Karalliedde J; Buckingham RE Drug Saf; 2007; 30(9):741-53. PubMed ID: 17722967 [TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone or pioglitazone in type 2 diabetes? de Vries CS; Russell-Jones DL BMJ; 2009 Aug; 339():b3076. PubMed ID: 19690344 [No Abstract] [Full Text] [Related]
10. The safety of thiazolidinediones. Tolman KG Expert Opin Drug Saf; 2011 May; 10(3):419-28. PubMed ID: 21366501 [TBL] [Abstract][Full Text] [Related]
11. Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. Berthet S; Olivier P; Montastruc JL; Lapeyre-Mestre M BMC Clin Pharmacol; 2011 May; 11():5. PubMed ID: 21609444 [TBL] [Abstract][Full Text] [Related]
13. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs? Buckingham RE; Hanna A Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890 [TBL] [Abstract][Full Text] [Related]
16. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Khanderia U; Pop-Busui R; Eagle KA Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014 [TBL] [Abstract][Full Text] [Related]
17. [Heart failure with thiazolidinedione treatment: what do we know today?]. Erdmann E Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858 [TBL] [Abstract][Full Text] [Related]
18. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. Loke YK; Kwok CS; Singh S BMJ; 2011 Mar; 342():d1309. PubMed ID: 21415101 [TBL] [Abstract][Full Text] [Related]
19. Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Page RL; Gozansky WS; Ruscin JM Pharmacotherapy; 2003 Jul; 23(7):945-54. PubMed ID: 12885108 [TBL] [Abstract][Full Text] [Related]
20. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Hollenberg NK Am J Med; 2003 Dec; 115 Suppl 8A():111S-115S. PubMed ID: 14678876 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]